Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Open Label Study to Evaluate the Long-term Safety and Tolerability of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis

NCT02634307 is registered in ClinicalTrials.gov with Biogen as lead sponsor.

NCT NCT02634307
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02634307 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Open Label Study to Evaluate the Long-term Safety and Tolerability of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis
Lead sponsor
Biogen
Phase
Phase 3
Overall status
Completed
Start date
December 10, 2015
Completion date
November 11, 2021
Enrollment
1,057 (actual)
Sites
115

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis